Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Background Antiangiogenic agents have improved the prognosis of non-squamous non-small–cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor’s characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small–cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy.